Spots Global Cancer Trial Database for A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
Official Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination With Rituximab and Bendamustine (BR) vs. BR in Subjects With Treatment-Naїve Mantle Cell Lymphoma
Study ID: NCT06363994
Conditions
Study Description
Brief Summary: Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
Detailed Description:
Keywords
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
